Startups chasing the $100 billion market for weight-loss drugs

  • 📰 BusinessInsider
  • ⏱ Reading Time:
  • 66 sec. here
  • 3 min. at publisher
  • 📊 Quality Score:
  • News: 30%
  • Publisher: 51%

Belgique Nouvelles Nouvelles

13 startups vying for a slice of the $100 billion market for buzzy new weight-loss drugs

Form, based in Boston, works with employers to offer its weight-loss program to workers as an employee benefit. The program is also offered directly to consumers.

Patients meet with an obesity-medicine doctor once a month virtually and a registered dietitian a couple of times a month. The company's providers treat patients for obesity and related health conditions such as polycystic ovary syndrome or hypothyroidism, Form's CEO, Evan Richardson, said. Richardson said they address nutrition, exercise, and behavior change, and they work with patients' existing providers to ensure their medicines aren't causing weight gain.

Richardson said that meeting with Form providers is covered by patients' insurance plans. Patients are responsible for paying a $99 onboarding fee and any copayments, but there's no monthly subscription fee. Its doctors work to prescribe a treatment that's covered, whether it's a GLP-1 drug such as Wegovy or a lower-cost medicine like metformin. Richardson said that about 10% of Form's patients aren't prescribed a weight-loss drug but are able to achieve their weight goals over time because of Form's holistic care.

"We're practicing the subspecialty of obesity medicine," he said."We are not prescribing a medication and then walking away from that patient."Apoorva Mehta, the founder of Sunrise's parent company, Cloud Health Systems.

 

Merci pour votre commentaire. Votre commentaire sera publié après examen.
Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite:

 /  🏆 729. in BE

Belgique Dernières Nouvelles, Belgique Actualités